CHTT Chattem, Inc. (MM)

Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Chattem, Inc. ("Chattem" or the "Company") (NASDAQ:CHTT) arising from the Company’s announcement of its intent to be acquired by Sanofi-aventis (“Sanofi”). Under the terms of the proposed transaction, Chattem shareholders will receive $93.50 in cash for each Chattem share owned in a transaction with a total value of $1.9 billion. The investigation is focused on the potential unfairness of the price to Chattem shareholders and the process by which the Company’s Board of Directors considered and approved the transaction.

If you are interested in discussing your rights as a Chattem shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, D.C. offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Chattem, Inc. (MM) (NASDAQ:CHTT)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Chattem, Inc. (MM) (NASDAQ:CHTT)
Historical Stock Chart
Von Dez 2023 bis Dez 2024